The research includes an oral presentation revealing that individuals with idiopathic hypersomnia experienced higher odds of comorbid conditions, such as cardiovascular disease.

Summary: Jazz Pharmaceuticals will present five abstracts at the 76th Annual American Academy of Neurology Meeting in Denver that focus on narcolepsy and idiopathic hypersomnia. Key findings include a real-world claims analysis showing increased risks of comorbid conditions with idiopathic hypersomnia and research on the benefits of low-sodium Xywav for sleep inertia and narcolepsy treatment. The meeting will feature both oral and poster presentations.

Key Takeaways: 

  • An oral presentation will detail results from the Real-World Idiopathic Hypersomnia Total Health Model (RHYTHM) study, revealing higher odds of comorbid conditions, including cardiovascular issues, in individuals with idiopathic hypersomnia compared to those without.
  • Two posters will assess the impact of Xywav oral solution on sleep inertia in individuals with idiopathic hypersomnia, presenting data from a phase 3 trial, demonstrating its efficacy as the first low-sodium oxybate.
  • A poster from the SEGUE study will report final results on adults with narcolepsy transitioning from high-sodium Xyrem to low-sodium Xywav, showing minimal dosage adjustments required for the switch.
  • Another poster will review data from five clinical studies evaluating the effects of high-sodium oxybates on sleep quality and architecture in narcolepsy patients, indicating their effectiveness in improving sleep measures despite the high-sodium content.

Jazz Pharmaceuticals plc will present one oral presentation and four poster presentations on narcolepsy and idiopathic hypersomnia at the 76th Annual American Academy of Neurology Meeting, which will take place April 13-18 in Denver.

A key oral presentation will detail results from a real-world claims analysis that demonstrated the increased risk of comorbid conditions, such as stroke or cardiovascular disease, in individuals living with idiopathic hypersomnia compared to those without the condition. 

Poster presentations include the evaluation of Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution on sleep inertia and sleep quality in patients with idiopathic hypersomnia and narcolepsy, along with detailed findings from the SEGUE study on transitioning narcolepsy patients from high-sodium to low-sodium oxybate treatments.

“Jazz’s presentations at the 2024 AAN Annual Meeting reflect our leadership in sleep and rare epilepsies, as well as our commitment to developing therapies for debilitating, and often overlooked, neurological disorders,” says Rob Iannone, MD, MSCE, executive vice president and global head of research and development of Jazz Pharmaceuticals, in a release. “We remain committed to expanding our knowledge of the patient experience, including the real-world impact and effectiveness of our products, in order to achieve our purpose of transforming the lives of patients and their families.”

Highlights at the 2024 AAN Annual Meeting include:

  • An oral presentation showcasing results from the Real-World Idiopathic Hypersomnia Total Health Model (RHYTHM) study which, using claims data, compared the comorbid conditions of individuals diagnosed with idiopathic hypersomnia with those experienced by individuals without idiopathic hypersomnia. Results revealed that individuals with idiopathic hypersomnia experienced higher odds of comorbid conditions across multiple clinical categories, including cardiovascular conditions, reaffirming the importance of considering the patient’s full clinical profile when evaluating treatment options for patients living with idiopathic hypersomnia.
  • Two posters assessing the impact of Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, the first and only low-sodium oxybate, on sleep inertia in individuals living with idiopathic hypersomnia, including results from a phase 3 trial.
  • One poster reporting the final results from the SEGUE study of adults with narcolepsy transitioning from Xyrem (sodium oxybate) oral solution, a high-sodium oxybate, to Xywav, showing that participants switched from high-sodium to low-sodium oxybate with minimal adjustments to their dosing.
  • A poster reviewing key data from five clinical studies evaluating the impact of all once- and twice-nightly high-sodium oxybates on sleep quality, sleep architecture, and measures of disrupted nighttime sleep in narcolepsy. The review found that oxybate was effective in improving measures of sleep architecture and disrupted nighttime sleep in patients with narcolepsy. Xyrem is indicated for the treatment of cataplexy and/or excessive daytime sleepiness in narcolepsy patients.

The 2024 AAN Annual Meeting abstracts are available here.

Photo 142024457 © Mary981 | Dreamstime.com